📈 Price History

Ratio Health

— Excellent

— Good

— Average

— Poor

By Category

📊 Sector Averages

About

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally.

Key Ratios Snapshot

📈 Growth Pattern

⚡ Latest Quarter —

See full financials →

📊 Quick Scorecard

Loading…

🔍 Concall Decoded

🎙 Management Tone Tracker Confident Specific → Stable 4 quarters analysed

Q2 2025

Confident Specific

The CEO repeatedly used phrases like 'exceptional 2Q performance', 'new high watermark', 'cement our commitment to profitable growth', and 'dispelling any confusion' showing clear command of narrative. He gave specific numbers and milestones, directly addressed competitive noise and regulatory concerns without hedging.

Q3 2025

Confident Specific

Management repeatedly used phrases like 'extremely proud of our strong results', 'very encouraged by year-over-year growth', 'laser-focused on capitalizing on momentum', and provided specific financial figures (revenue, margins, guidance range) with conviction.

Q4 2025

Confident Specific

Management uses phrases like 'banner quarter', 'best operational performance to date', 'exceedingly confident', and provides specific growth figures and guidance. They also address external challenges directly and express pride in team resilience.

Q1 2026 latest

Confident Specific

Management used language like 'strong start,' 'solid quarter,' 'highly encouraged,' and 'early innings of long-term growth.' They provided specific numbers on revenue, operating profit, and cash, and detailed multiple growth initiatives with timelines.

Guidance Reliability Pending · <3Q data

Investor Lens

The investment thesis remains largely unchanged after this call. Management reiterated strong Q1 execution and full-year guidance despite headwinds from the Transplant Modernization Act and competitive confusion. The new CHOPS device addresses a key clinical trial bottleneck and opens a path to capture cold storage market share without cannibalizing OCS. However, near-term margin pressure from heavy investment in multiple growth initiatives (Kidney, Gen 3.0, Europe) tempers near-term profitability. Key catalysts to watch: IDE approval for CHOPS in early Q3, pace of ENHANCE/DENOVO enrollment, and any updates on OPO bidding or European NOP tenders. The strong cash position provides flexibility, but the growth trajectory depends on execution of these ambitious initiatives.

AI-generated concall tone analysis · Updated 2026-06-09 · Not investment advice

🎙 Management Tone Confident Specific → Stable 4 quarters Full tone analysis in Intelligence →

📊 MIXED TransMedics Q1 2026 revenue $174M, up 21% YoY; eyes OCS Kidney and CHOPS launches.

Revenue & Profitability

Total revenue for Q1 2026 was $174 million, representing 21% year-over-year growth and 8% sequential growth. U.S. transplant revenue was $167 million (up 20% YoY), international revenue was $5.6 million (up 39% YoY). Adjusted operating income was $18.1 million (10.4% margin), and adjusted net income was $11 million ($0.30 per diluted share). Cash and equivalents stood at $462 million at quarter-end.

Outlook

Management reiterated full-year 2026 revenue guidance of $727-757 million (20-25% growth). They see strong underlying demand driven by increasing OCS case volume and clinical adoption, despite transient negative impact from the U.S. Transplant Modernization Act on OPO performance and donor numbers. International expansion and new product launches are expected to expand total addressable market over the mid-to-long term.

Growth Drivers

Key growth levers include: ENHANCE Heart and DENOVO Lung clinical programs (enrollment expected to accelerate with CHOPS control arm in Q3 2026); OCS Kidney program (targeting U.S. IDE submission early 2027); Gen 3.0 technology upgrades for heart, lung, and liver systems; NOP Europe expansion (Italy hubs, Benelux, and partnership with PAD Aviation); and CHOPS, a controlled hypothermic device for cold storage segments. The company also plans to bid for donor service areas from decommissioned OPOs under transplant modernization.

Balance Sheet & CapEx

TransMedics is investing significantly in R&D (adjusted R&D up 45% YoY), NOP network strengthening, IT capabilities, a new headquarters in Somerville, and product development in Mirandola, Italy. The company also entered a definitive agreement with PAD Aviation to create a European air logistics network. No specific CapEx dollar figures were provided, but investments are expected to be front-loaded in 2026.

Margins

Q1 2026 gross margin was ~58%, down 331 basis points year-over-year due to inventory build for clinical programs and NOP investment. Long-term gross margin target remains ~60%. Adjusted operating margin was 10.4% in Q1, below last year's level due to accelerated investments. Management expects near-term pressure but sees operating leverage from Gen 3.0 platform, kidney program, and scaling of NOP over time.

Key Risks

Key risks flagged include: transient disruption from the U.S. Transplant Modernization Act leading to lower donor numbers; competitive dynamics causing clinical trial enrollment delays; near-term pressure on gross and operating margins from strategic investments; and fuel price exposure (though management believes it can be managed through network efficiency and surcharges). No other specific risks were highlighted.

Generated by AI · Q1 2026 results · Not investment advice

✓ 📞 Earnings Call Transcripts (5 quarters) submit a missing quarter

🔍

🔎 See cross-company document search → ?

📞 Earnings Call Transcripts (5)

Q2 2026 Q2 2026 2026-08-04

Record Q2 revenue of $190M was driven by strong growth in OCS case volume, clinical services, and logistics, with service revenue outpacing product revenue. Raised 2026 revenue guidance to $737–$757M, excluding PAD Aviation, and expect continued investment in growth initiatives and international expansion.

Q1 2026 Q1 2026 2026-05-05

Q1 2026 delivered 21% revenue growth and strong operational execution, despite regulatory headwinds and donor supply volatility. Major investments in technology, logistics, and international expansion support a reiterated 2026 revenue guidance of $727–$757 million.

Q4 2025 Q4 2025 2026-02-24

Delivered record 2025 results with 37% revenue growth, strong operating leverage, and robust cash flow. 2026 guidance targets 20–25% revenue growth, supported by clinical adoption, new programs, and international expansion, despite near-term margin pressures.

Q3 2025 Q3 2025 2025-10-29

Q3 2025 saw 32% year-over-year revenue growth to $143.8M, with strong gains in all organ segments and logistics. Gross margin improved to 59%, and net income rose 477% year-over-year. Full-year revenue guidance was raised to $595–$605M, reflecting continued momentum and international expansion.

Q2 2025 Q2 2025 2025-07-30

Q2 delivered record revenue and profit growth, driven by strong U.S. transplant volumes and logistics services. Full-year guidance was raised, with continued investment in R&D, infrastructure, and international expansion supporting long-term growth and margin expansion.

📊 Analysis Methodology

This comprehensive investment analysis was conducted using The Finmagine™ Stock Analysis & Ranking Methodology, a proprietary framework that systematically evaluates stocks across five critical dimensions: Financial Health, Growth Prospects, Competitive Positioning, Management Quality, and Valuation.

🎯

Discover Our Proven Investment Framework Learn how we analyze and rank stocks using advanced quantitative models, multi-dimensional scoring systems, and dynamic discriminatory ranking techniques that have guided successful investment decisions across market cycles.

📊 Explore The Finmagine™ Methodology

A comprehensive, bias-free framework for analyzing and ranking stocks by Financial Strength, Growth Potential, Competitive Edge, Management Quality, and Value.

⚠️ Important Disclaimers — Please read without fail.

Investment Risk:
Investing in securities, including US equities and ETFs, involves inherent risks including the potential loss of principal. All investments are subject to market fluctuations, economic conditions, regulatory changes, and other factors that may affect their value. Past performance is not indicative of future results. This analysis is provided for informational and educational purposes only and should not be construed as investment advice under any circumstances.

No Investment Recommendation:
This analysis does not constitute, nor should it be interpreted as, an offer, solicitation, or recommendation to buy, sell, or hold any securities or financial products. Investors are strongly advised to conduct their own independent research and due diligence and to consult with a licensed financial advisor or an SEC-registered investment adviser before making any investment decisions, taking into account their individual financial situation, risk tolerance, and investment objectives.

Not SEC-Registered:
Finmagine is not registered as an investment adviser with the U.S. Securities and Exchange Commission (SEC) or any state securities authority. Nothing on this platform constitutes investment advice as defined under the Investment Advisers Act of 1940.

Conflict of Interest Disclosure:
The author and/or analyst may currently hold or have previously held positions in the securities discussed. Any such positions are not intended to influence the objectivity or independence of the analysis. This research is produced independently and is not sponsored, endorsed, or commissioned by any company or institution.

Information Sources:
The analysis is based on publicly available information including SEC filings (10-K, 10-Q), annual reports, management commentary, and publicly available financial data. Information is believed to be accurate as of the date of publication but may be subject to change without notice. Readers are encouraged to independently verify all information before acting upon it.

Forward-Looking Statements:
This analysis may contain forward-looking statements, forecasts, or projections that are inherently subject to risks, uncertainties, and assumptions. Actual results may differ materially from those expressed or implied. Finmagine does not undertake any obligation to update such statements in the future.

Limitation of Liability:
The content is provided "as is" without any warranties, express or implied. Finmagine expressly disclaims any liability for errors, omissions, or any losses incurred as a result of reliance on the information provided. Readers assume full responsibility for their investment decisions.